# Decitabine+BUCY vs BUCY Conditioning Regimen for MLL+ Acute Leukemia Undergoing Allo-HSCT

> **NCT03596892** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 122 (estimated)

## Conditions studied

- Allogeneic Hematopoietic Stem Cell Transplantation
- Conditions
- Mixed-lineage-leukemia (MLL)-Rearranged Acute Leukemia

## Interventions

- **DRUG:** Decitabine
- **DRUG:** Busulfan (BU)
- **DRUG:** Cyclophosphamide (CY)

## Key facts

- **NCT ID:** NCT03596892
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-07
- **Primary completion:** 2021-06
- **Final completion:** 2022-06
- **Target enrollment:** 122 (ESTIMATED)
- **Last updated:** 2018-07-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03596892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03596892, "Decitabine+BUCY vs BUCY Conditioning Regimen for MLL+ Acute Leukemia Undergoing Allo-HSCT". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03596892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*